Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (111-120 of 437) with videos related to

Pageof 44
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2010
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment studyMartin Reck, Nico van Zandwijk, Cesare Gridelli, et al.
Lung Cancer (Amsterdam, Netherlands)|December 25, 2002
Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II studyMartin Reck, Urzula Jagos, Franziska Grunwald, et al.
Respiratory Research|July 26, 2018
Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesisTorsten Goldmann, Gernot Zissel, Henrik Watz, et al.
Onkologie|June 17, 2011
[Follow-up, complications and their treatment in the surgical, radiotherapeutic and pharmacological treatment of lung cancer]Axel Armbrecht, Andreas Gröschel, Christoph Pöttgen, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2008
Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinomaMartin Reck, Hans-Nikol Macha, Sonia Del Barco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2019
Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung CancerDavid F Heigener, Keith M Kerr, Gavin M Laing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancerGeorge R Blumenschein, Ulrich Gatzemeier, Frank Fossella, et al.
Expert Review of Respiratory Medicine|December 13, 2019
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with <i>EGFR</i> mutationsMartin Reck, Geetha Shankar, Anthony Lee, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2022
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationshipKazuhiko Nakagawa, Edward B Garon, Ling Gao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2017
Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 StudyMartin Reck, Fiona Taylor, John R Penrod, et al.
Pageof 44

Showing results (111-120 of 437) with videos related to

Sort By:
Pageof 44
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2010
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment studyMartin Reck, Nico van Zandwijk, Cesare Gridelli, et al.
Lung Cancer (Amsterdam, Netherlands)|December 25, 2002
Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II studyMartin Reck, Urzula Jagos, Franziska Grunwald, et al.
Respiratory Research|July 26, 2018
Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesisTorsten Goldmann, Gernot Zissel, Henrik Watz, et al.
Onkologie|June 17, 2011
[Follow-up, complications and their treatment in the surgical, radiotherapeutic and pharmacological treatment of lung cancer]Axel Armbrecht, Andreas Gröschel, Christoph Pöttgen, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2008
Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinomaMartin Reck, Hans-Nikol Macha, Sonia Del Barco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2019
Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung CancerDavid F Heigener, Keith M Kerr, Gavin M Laing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancerGeorge R Blumenschein, Ulrich Gatzemeier, Frank Fossella, et al.
Expert Review of Respiratory Medicine|December 13, 2019
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with <i>EGFR</i> mutationsMartin Reck, Geetha Shankar, Anthony Lee, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2022
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationshipKazuhiko Nakagawa, Edward B Garon, Ling Gao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2017
Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 StudyMartin Reck, Fiona Taylor, John R Penrod, et al.
Pageof 44